Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	DС	20549	
vasiliigton,	D.C.	20049	

STATEMENT	OF CHANGE	S IN BENEFIC	IAL OWNERSHI	P

	OMB APPROVAL										
	OMB Number: 3235-0287										
	Estimated average burden										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Yea Christopher					2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [KALV]									all app		ng Per	10% Ov	vner	
(Last)	`	irst) (I	Middle	,	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2024									X C	belov	er (give title v) DEVELO	PME	Other (s below) CNT OFFI	` '
55 CAMBRIDGE PARKWAY, SUITE 901E				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)	IDGE M	IA 0	2142			X Form filed by One Reporting Persor Form filed by More than One Repor Person													
(City)	(S	state) (2	Zip)		l _□ ,	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a cor									uction or writt	en pla	n that is inter	nded to	
Table I - Non-Deriva						satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. re Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/				Execution Date			3. Transaction Code (Instr. 8)					l and 5) Se Be Ov		Securities Beneficially Dwned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Trar		ported ansaction(s) str. 3 and 4)			(Instr. 4)	
Common Stock 02/14/2			02/14/20)24			S ⁽¹⁾		39,886	D	\$15.00)93	93 66,160			D			
		Tal	ble II	- Derivati (e.g., pu							oosed of, convertib				Owne	d			
1. Title of Derivative Conversion or Exercise Price of Derivative Security		ution Date,		saction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date			7. Title Amou Secur Under Derive Secur 3 and	nt of ities rlying ative ity (Instr. 4)	Der Sec	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Ownership Form:	Beneficial Ownership (Instr. 4)			
					Code	ode V (A) (D)			Date Exerc	isable	Expiration Date	Title	Number of Shares						

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

/s/ Benjamin L. Palleiko, Attorney-in-Fact

** Signature of Reporting Person Date

02/16/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.